Economics / Business
GlaxoSmithKline agrees to reduce by 70% the order of the German government H1N1 influenza vaccines
LONDON, 12 Jan. (EUROPA PRESS) --
The British laboratory GlaxoSmithKline has reached an agreement with the Ministry of Health of Germany to reduce by 70% the size of the order of vacum to combat influenza H1N1, which shall then to 34 million doses, compared to about 50 million originally requested by Germany government.
The pharmaceutical company said that at the beginning of the pandemic, taking into account previous experience, immunization programs involved the supply of two doses of the vaccine, but admitted that the clinical trial data showed a strong immune response with only one dose This has prompted the authorities to review their orders.
Thus, GSK said that currently is in talks with several governments in relation to specific country needs to address the pandemic, including those governments that have changed their immunization programs.
The chairman of the biological division of GSK, Jean Stephenne, said that "pandemics, by their nature are unpredictable and recognize that the needs of governments have changed."
Source: europa press
http://translate.google.es/translat...ra-gripe-h1n1-20100112174446.html&sl=es&tl=en
GlaxoSmithKline agrees to reduce by 70% the order of the German government H1N1 influenza vaccines
LONDON, 12 Jan. (EUROPA PRESS) --
The British laboratory GlaxoSmithKline has reached an agreement with the Ministry of Health of Germany to reduce by 70% the size of the order of vacum to combat influenza H1N1, which shall then to 34 million doses, compared to about 50 million originally requested by Germany government.
The pharmaceutical company said that at the beginning of the pandemic, taking into account previous experience, immunization programs involved the supply of two doses of the vaccine, but admitted that the clinical trial data showed a strong immune response with only one dose This has prompted the authorities to review their orders.
Thus, GSK said that currently is in talks with several governments in relation to specific country needs to address the pandemic, including those governments that have changed their immunization programs.
The chairman of the biological division of GSK, Jean Stephenne, said that "pandemics, by their nature are unpredictable and recognize that the needs of governments have changed."
Source: europa press
http://translate.google.es/translat...ra-gripe-h1n1-20100112174446.html&sl=es&tl=en
